La radiofréquence a-t-elle des soucis à se faire ?Mohamed B, Emara Elzanan M.H, Elshamy M, Tai C. Royaume-Uni/Egypte. PERCUTANEOUS INJECTION OF ETHANOL AND MITOXANTRONE VERSUS RADIOFREQUENCY ABLATION IN THE TREATMENT OH HEPATOCELLULAR CARCINOMA.
Des antibiotiques moins longtemps !Britt ten Böhmer B, Haal S, Balkema S, Depla A.C.T.M, Fockens P, Van Hooft J.E, Jansen J.M, Kuiken S.D, Liberov B.I, van Soest E, Voermans R.P. Pays-Bas. INFLUENCE OF ANTIBIOTIC DURATION IN CHOLANGITIS AFTER SUCCESSFUL DRAINAGE BY ERCP.
Le retour des antibiotiques dans la maladie de Crohn ?Graham D - Houston / USA PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADD-ON FIXED-DOSE ANTI-MYCOBACTERIAL THERAPY (RHB-104) IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (MAP US)
La transplantation fécale pour traiter la colite à clostridium réfractaire au traitement antibiotiqueIaniro G.1, Masucci L.2, Quaranta G.2, Simonelli C.1, Lopetuso L.R.1, Napoli M.1, Sanguinetti M.2, Gasbarrini A.1, Cammarota G.1 1IRCCS Fondazione Agostino Gemelli University Hospital, Digestive Disease Center, Rome, Italy, 2IRCCS Fondazione Agostino Gemelli University Hospital, Microbiology Institute, Rome, ItalyOP181 - RANDOMISED CLINICAL TRIAL: SINGLE INFUSION- VERSUS MULTIPLE INFUSION-FAECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE CLOSTRIDIUM DIFFICILE INFECTION REFRACTORY TO ANTIBIOTICS
Combothérapie en cas de switch après immunisation d’un premier anti-TNF !ROBLIN X. - France / INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL.
Avoir foi(e) en les statines ?Goh M.J, Paik N, Sinn D.H, Kang W, Gwak G.-Y, Paik Y.-H, Choi M.S, Lee J.H, Koh K.C, Paik S.W. Corée du Sud. STATIN USE ANS THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B.
Cirrhose : prévenir la réadmission précoce ?Franco L.M, Rodriguez M, Navascues C.A, Antón S, Ferrusquía J, Ríos A, Fraile M, Gonzalez-Dieguez L, Valle C, Varela M, De la Vega J, Graviss E, Nguyen D, Victor D.W. Espagne. RISK SCORE MODEL TO PREDICT EARLY READMISSION IN DECOMPENSATED CIRRHOSIS.
Cirrhose : les antibiotiques pas si automatiques ?Figueiredo L.M, Rafael M.A, Alexandrino G, Martins A, Oliveira A.M, Carvalho R, Santos Nunes L, Horta D, Lourenço L.C.C, Costa M.N, Reis J. Portugal. RISK FACTORS FOR THE EMERGENCE OF MULTIDRUG-RESISTANT ORGANISMS IN LIVER CIRRHOSIS.
La transplantation fécale pour traiter le syndrome de l’intestin irritable ? Le débat reste ouvert !Halkjær S.I.1, Christensen A.H.2, Lo B.Z.S.1, Browne P.3, Günther S.2, Hansen L.H.3, Petersen A.M.1 1Copenhagen University Hospital Hvidovre, Department of Gastroenterology, Hvidovre, Denmark, 2Aleris-Hamlet Hospitaler, Søborg, Denmark, 3Aarhus University, Department of Environmental Science, Roskilde, Denmark, OP035 - FECAL MICROBIOTA TRANSPLANTATION ALTERS GUT MICROBIOTA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY
POEM contre Heller dans l’achalasie, round 1Eduardo Turiani Hourneaux de Moura, Brésil, A randomized controlled trial comparing peroral endoscopic myotomy (POEM) versus laparoscopic heller myotomy in the treatment of achalasia SOP1
Microbiote intestinal et syndrome de l’instestin irritable : l’oeuf ou la poule ?Brunkwall L., Nilsson P., Ericson U., Orho-Melander M., Ohlsson B. Lund University, Malmö, Sweden, OP030 - GUT MICROBIOTA CHARACTERISTICS ASSOCIATE WITH IRRITABLE BOWEL SYNDROME AND SPECIFIC BOWEL SYMPTOMS IN A POPULATION-BASED STUDY FROM SWEDEN
L’ustekinumab dans la RCH : ça marche !Sands Bruce E. - USA / SAFETY AND EFFICACY OF USTEKINUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 UNIFI STUDY
L’injection de cellules souches : un nouvel espoir dans le traitement des fistules ano-périnéales pour les malades de Crohn ?Barnhoorn M.1, Molendijk I.1, Bonsing B.A.2, Roelofs H.3, Maljaars J.P.W.1, Peeters K.2, Wasser M.N.J.M.4, Oosten L.E.M.3, Dijkstra G.5, van der Woude C.J.6, Duijvestein M.7, Veenendaal R.A.1, Zwaginga J.3, Verspaget H.W.1, Fibbe W.E.3, Hommes D.W.1,8, Van der Meulen - De Jong A.1 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Surgery, Leiden, Netherlands, 3Leiden University Medical Center, Immunohematology and Blood Transfusion, Leiden, Netherlands, 4Leiden University Medical Center, Radiology, Leiden, Netherlands, 5UMC Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 6Erasmus Medical Center, Gastroenterology, Rotterdam, Netherlands, 7AMC, Gastroenterology and Hepatology, Amsterdam, Netherlands, 8University of California Los Angeles, Digestive Diseases, Los Angeles, United States, OP060 - LONG-TERM EFFICACY AND SAFETY OF ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS FOR PERIANAL FISTULAS IN PATIENTS WITH CROHN'S DISEASE: A 4-YEAR FOLLOW-UP STUDY